Introduction: Patients with positive tauopathy but negative Ab 42 (A2T1) in the cerebrospinal fluid (CSF) represent a diagnostic challenge. The Ab 42/40 ratio supersedes Ab 42 and reintegrates "false" A2T1 patients into the Alzheimer's disease spectrum. However, the biomarker and clinical characteristics of "true" and "false" A2T1 patients remain elusive. Methods: Among the 509 T1N1 patients extracted from the databases of three memory clinics, we analyzed T1N1 patients with normal Ab 42 and compared "false" A2T1 with abnormal Ab 42/40 ratio and "true" A2T1 patients with normal Ab 42/40 ratio, before CSF analysis and at follow-up. Results: 24.9% of T1N1 patients had normal Ab 42 levels. Among them, 42.7% were "true" A2T1. "True" A2T1 had lower CSF tau P181 than "false" A2T1 patients. 48.0% of "true" A2T1 patients were diagnosed with frontotemporal lobar degeneration before CSF analysis and 64.0% at follow-up, as compared with 6% in the "false" A2T1 group (P , .0001). Discussion: Frontotemporal lobar degeneration is probably the main cause of "true" A2T1 profiles.
Introduction
Cerebrospinal fluid (CSF) biomarkers have redesigned Alzheimer's disease (AD) diagnosis [1] [2] [3] . The major interest of CSF biomarkers rests upon their reflection of brain pathology: several studies have shown that CSF Ab 42 levels are inversely correlated with cerebral Ab load [4] [5] [6] , whereas increased CSF total tau (T-tau) and phosphorylated tau (tau 181P ) levels reflect the burden of neurofibrillary pathology [6] [7] [8] . Although CSF T-tau is an unspecific marker of neuronal death [9] [10] [11] , tau 181P and Ab 42 have a high specificity for AD. Tau 181P is not or slightly increased in other tauopathies and was shown to outperform the two other biomarkers taken in isolation for differential dementia diagnosis [12] [13] [14] [15] . In 2018, the AT(N) classification system proposed by the 2018 National Institute of Aging-Alzheimer's Association (NIA-AA) research framework shifted the definition of AD from a syndromal to a biological construct [16] . This system validates CSF Ab 42 and tau 181P as suitable markers for amyloid (A) and tau (T) pathology, respectively, while T-tau is considered as a marker of neuronal injury [16, 17] . In the AT(N) scheme, AD patients are A1T1 by definition.
According to Jack's model, there is a temporal ordering of biomarker abnormalities in which biomarkers of Ab deposition become abnormal before biomarkers of tau pathology and neuronal injury [18] . So far, longitudinal studies show that most AD patients fit into this model [19, 20] . However, a vast number of patients present with A2T1 CSF profiles, that is, with abnormal tau and normal Ab biomarkers [21] [22] [23] [24] . This possibility of "conflicting" results was anticipated in the 2011 NIA-AA criteria for AD diagnosis. In such instances, biomarkers were deemed "uninformative," suggesting that results should simply not be taken into account [25, 26] . The recent AT(N) classification system goes one step further, as A2T1 patients are now labeled "suspected non-Alzheimer's pathophysiology" (SNAP) [16, 27] .
In recent years, a growing interest for the mechanisms of amyloid precursor protein cleavage has prompted the development of ELISA kits specific for other Ab species. In the CSF, the most abundant isoform is Ab 40 , whose levels show substantial interindividual variations. Because CSF Ab 42 concentration may also depend on overall Ab levels, it was suggested that an imbalance between CSF Ab 42 and Ab 40 (i.e., a decreased Ab 42/40 ratio) could supersede the mere decrease of CSF Ab 42 level as a biomarker of amyloid pathology [28] [29] [30] [31] [32] . Indeed, Ab 42/40 ratio was better correlated than Ab 42 with amyloid tracer retention in two positron emission tomography studies [31, 32] . Using the Ab 42/40 ratio allows to reclassify half of A2T1 patients (hereafter referred to as "false" A2T1, that is, abnormal CSF tau markers and normal Ab 42 but abnormal Ab 42/40 ratio) into the A1T1 group [33, 34] . Despite the relative scarcity of validation studies, the AT(N) system readily recognizes the Ab 42/40 ratio as a surrogate marker of amyloid pathology [16] .
However, the clinical phenotype of A2T1 patients remains poorly studied. Positing that Ab 42/40 is the best CSF amyloid biomarker, "false" A2T1 patients should be clinically indistinguishable from A1T1 patients. Conversely, when using the Ab 42/40 ratio instead of Ab 42 , 10% to 13% of patients still display a "true" A2T 1 CSF profile (i.e., abnormal CSF tau markers and normal Ab 42 and Ab 42/40 ratio) [33, 34] . "True" A2T1 patients should have a clinical phenotype that differs from the one of both "false" A2T1 and typical A1T1 patients. In this context, the objectives of this retrospective multicenter study were to (1) determine the proportion of A2T 1 CSF profiles in routine clinical care; (2) compare the clinical diagnoses made before CSF analysis; and (3) compare the clinical phenotype at follow-up in A2T1 patients separated according to the Ab 42/40 ratio.
Patients and methods

Subjects
Subjects were recruited between November 14, 2012 and December 31, 2015 from Paris, Lille, and Nantes Memory Resource and Research Centres (MMRC). Inclusion criteria were fivefold: (1) available CSF with AD biomarkers, including Ab 42 , Ab 40 , T-tau, and tau 181P (quantitative determination of Ab 40 and Ab 42/40 ratio is routine in the three memory clinics); (2) high CSF tau 181P (tau 181P 60 pg/mL); (3) mild cognitive impairment (MCI) or dementia; (4) presence of biomarkers of neurodegeneration or neuronal injury (N1) on 18F-fluorodeoxyglucose-PET or MRI, and/or high CSF total-tau [16] ; and (5) available medical records and neuropsychological assessments performed before the results of CSF biomarkers were made available. Exclusion criteria were as follows: (1) subjective cognitive decline;
(2) unconventional indications of AD CSF biomarkers analysis (e.g., systematic biomarkers analysis following a lumbar puncture [LP] performed for another indication); (3) significant comorbidities, including concomitant nondegenerative and nonvascular neurological disorder.
Clinical diagnoses
All recruiting centers were tertiary referral memory clinics. These centers use the same clinical and biochemical procedures and international validated criteria for AD and all other dementia. Patients had a thorough examination, including clinical, neurological, and neuropsychological evaluations and brain imaging, as recommended by the Haute Autorit e de Sant e (French Health Authority). We collected the diagnosis made by the clinician before the LP and the last diagnosis made after the LP at follow-up. To avoid the bias due to the knowledge of CSF biomarkers results, the main analysis was based on the diagnosis evoked by the clinician before the CSF results.
In addition, medical records and neuroimaging studies were analyzed in retrospect by H.P.C., T.B.N., C.P., and T.L., and confronted to current diagnostic criteria. We used the 2011 NIA-AA criteria for probable AD dementia [26] . At the MCI stage, AD diagnosis was only raised when the MCI clinical and cognitive syndrome was consistent with AD, according to the NIA-AA criteria [25] . Vascular cognitive impairment, behavioral variant of frontotemporal dementia (bvFTD), primary progressive aphasia (PPA) syndromes, Lewy body dementia, progressive supranuclear palsy syndrome (PSPS), and corticobasal syndrome (CBS) were defined according to the corresponding criteria [35] [36] [37] [38] [39] [40] . In case of discrepancy with the clinician's diagnosis, another diagnosis was suggested.
AD was deemed atypical in case of posterior cortical syndrome, primary logopenic aphasia or frontal/executive variant, as well as in mixed disease (concomitant vascular cognitive impairment and/or Lewy body disease) or when neuroimaging studies were not congruent with AD.
Cerebrospinal fluid analysis
LPs were performed using a 25-gauge needle, and CSF samples were collected in a 5-mL polypropylene tube in Nantes (catalog number 62.558.201; Sarstedt, N€ umbrecht, Germany) or in a 10-mL polypropylene tube in Lille and Paris (catalog number 62.610.201; Sarstedt, N€ umbrecht, Germany). Each CSF sample was transferred at 4 C to the corresponding local laboratory within 4 hours after collection and was then centrifuged at 1000 g (Lille and Paris) or 2100 g (Nantes) for 10 minutes at 4 C. A small amount of CSF was used to perform routine analyses, including total cell count, bacteriological examination, and total protein and glucose levels. The CSF was aliquoted in 1.5-mL polypropylene tubes (Lille and Paris) or 2-mL polypropylene tubes (Nantes) and stored at 280 C to await further analysis. CSF Ab 40 , Ab 42 , T-tau, and tau 181P were measured in each local laboratory using a commercially available sandwich enzyme-linked immunosorbent assay (INNOTEST; Fujirebio Europe NV, Gent, Belgium) according to the manufacturer's instructions.
AD biomarker cutoffs
Cutoff values used in clinical routine for P-tau were based on the results of the French multicenter study setting up the harmonization of sampling procedures and collection tubes, to which the three MRRCs involved in the current work participated [41] . Cutoff values for Ab 42 and Ab 42/40 were set at, respectively, ,800 pg/mL and ,0.065 following another French multicenter study involving our two of our three MMRCs [34] . Pathological results were defined as follows: Ab 42 ,800 pg/mL, T-tau 350 pg/mL, and tau 181P 60 pg/mL. Although the AT(N) classification system is intended for research and not for clinical practice [16] , we chose to use its nomenclature for brevity. A1T1 profiles were defined by tau 181P 60 pg/mL and Ab 42 ,800 pg/mL. A2T1 profiles were defined by tau 181P 60 pg/mL and Ab 42 800 pg/mL. A2T 1 CSF profiles were further subdivided into "false" A2T1 profiles (Ab 42/40 ratio ,0.065, congruent with the presence of amyloid pathology) and "true" A2T1 profiles (normal Ab 42/40 ratio 0.065, congruent with the absence of amyloid pathology).
Statistical analysis
Qualitative variables were expressed as frequencies and percentages. Quantitative variables were expressed as mean 6 standard deviation. Normality of distributions was assessed graphically and using the Shapiro-Wilk test.
"True" and "false" A2T1 patients were compared using chi-square test (or Fisher's exact test when the expected cell frequency was ,5) for qualitative variables, and Student t-test (or Mann-Whitney U test in case of non-Gaussian distribution) for quantitative variables.
In the "True" A2T1 patient group, different parameters were compared according to diagnosis before CSF results. Qualitative parameters were analyzed using chi-square test or Fisher's exact test. Analysis of variance (or Kruskal-Wallis test in case of non-Gaussian distribution) was used for quantitative parameters.
A sensitivity analysis was systematically performed by including the study site (Lille, Nantes, or Paris) as a covariate, using a logistic regression to compare "true" and "false" A2T1 patients.
Statistical testing was performed at the two-tailed a level of 0.05. Data were analyzed using the SAS software package, release 9.4 (SAS Institute, Cary, NC).
Results
Study population
The study included 1253 patients who underwent a CSF study for biomarker analysis, among which 509 (40.6%) had pathological levels of tau 181P .
The population of the study was further divided according to Ab 42/40 ratio. Most of the patients with pathological levels of tau 181P were A1T1 (n 5 362, 75.1%). One hundred twenty patients were A2T1 (24.9% of patients with pathological tau 181P , and 9.8% of all patients). Within this subgroup, 67 (57.3%) had abnormal Ab 42/40 ratios ("false" A2T1 profiles) while 50 (42.7%) had normal Ab 42/40 ratios ("true" A2T1 profiles) ( Fig. 1 ). Hence, Ab 42/40 ratio allowed reclassifying more than half of the A2T1 patients into the AD spectrum.
3.2. CSF biomarkers in "true" and "false" A2T1 patients CSF biomarker levels were statistically different between both groups (Table 1 ). "False" A2T1 patients had lower Ab 42 Tau 181P and T-tau were significantly higher in the "false" (102.4 6 37.6 and 739.9 6 405.6) than in the "true" A2T1 group (74.4 6 12.3 and 475.2 6 147.1; P , .001 and P , .001). The proportion of patients with concomitant pathological values of T-tau and tau 181P was higher in the "false" (94.0%) than in the "true" A2T1 group (80.0%; P 5 .02). Yet in the "true" A2T1 group, tau 181P and T-tau levels were far beyond cutoff for a majority of patients (Fig. 2) . All results remained highly significant after including the study site as a covariate.
3.3. Clinical diagnoses before biomarkers analysis in "true" and "false" A2T1 patients A systematic comparison of the clinical data between "true" and "false" A2T1 groups was performed. There was no significant difference regarding age, gender, and MMSE scores (Table 1) .
Diagnoses made by the clinician before CSF biomarkers results were differently distributed between groups (P , .001). AD diagnosis was significantly more frequent in the "false" A2T1 (n 5 58, 86.6%) than in the "true" A2T1 group (n 5 20, 40.0%; P , .0001). Among the suspected AD diagnoses, typical amnestic presentations were more frequent among "false" A2T1 patients (n 5 42, 72.4% of AD diagnoses) than in "true" A2T1 patients (n 5 6, 30.0% of AD diagnoses; P 5 .0008).
Diagnoses of the frontotemporal lobar degeneration (FTLD) spectrum encompass bvFTD, nonfluent/agrammatic and semantic variants of PPA, CBS, and PSPS [42] . FTLD diagnoses were made for only four patients (6.0%) in the "false" A2T1 group, as opposed to 24 patients in the "true" A2T1 group (48.0%, P , .0001). Semantic variant PPA was the leading syndrome (10/24, 41.7%) followed by probable bvFTD (8/24, 33.3%). Four more patients had a clinical presentation consistent with a pure tauopathy (one with CBS, one with PSPS, two with apraxia of speech, and one with nonfluent/agrammatic PPA). The two remaining patients were classified as possible bvFTD and unclassifiable PPA.
Other etiologies (Lewy body disease, multidomain and executive MCI, VCI, psychiatric) were rarer and were not more represented in the "true" than in the "false" A2T1 group (P 5 1). Finally, the comparisons of clinical diagnoses remained significant after including the study site as a covariate.
Follow-up of patients with A2T1 profiles
In the "false" A2T1 group, 58/67 patients (87%) were diagnosed with AD before the LP, and the diagnosis did not change afterward for 50/58 patients (86%). Five of the nine remaining "false" A2T1 patients were diagnosed with AD during follow-up.
Among the 20/50 patients in the "true" A2T1 group diagnosed with AD before biomarker analysis, 7/20 patients fulfilled criteria for FTLD at follow-up (one with possible bvFTD, three with probable bvFTD, two with semantic PPA, and one with unclassifiable PPA). Among the 24/50 patients from the "true" A2T1 group diagnosed with FTLD before biomarker analysis, there was no change in diagnosis at follow-up ( Fig. 3 and Supplementary Table 1 ). In addition, two patients were found to bear a C9ORF72 gene mutation during follow-up.
Overall, 31/50 (62.0%) "true" A2T1 patients had a clinical diagnosis belonging to the FTLD spectrum after reviewing the clinical files: 12/31 fulfilled the clinical criteria for bvFTD (three possible bvFTD, seven probable bvFTD, two genetically confirmed bvFTD) and 19/31 for one of the FTLD variants (12 svPPA, two unclassifiable PPA, 5 PSP/CBS/nfPPA) (Supplementary Table 1 ).
Discussion
The main results of this retrospective multicenter study are that (1) in a real-life memory clinic setting, A2T1 patients defined by CSF Ab 42 were common; (2) the Ab 42/40 ratio used instead of Ab 42 was able to reclassify half of A2T1 patients (i.e., "false" A2T1 patients) into the A1T1 group; (3) the clinical phenotype of "true" A2T1 patients differed from the one of "false" A2T1 patients, with an overrepresentation of patients whose clinical presentation is congruent with FTLD.
Ever since the first report of its use in 1998 [43] , the Ab 42/40 ratio was repetitively shown to be superior to Ab 42 for AD diagnosis [37, 38] , including at the prodromal stage [29] , as well as for differential dementia diagnosis [30, 31, 44, 45] . In the present study, we showed that the Ab 42/40 ratio changes half of previously considered "uninformative" CSF profiles into A1T1, the biological definition of AD [16] . This result is strikingly similar to the ones of previous studies [33, 34, 46] .
Although the new NIA-AA criteria recently took the leap to a biomarker-based diagnosis of AD, which renders the clinical correlations accessory, our clinical data support the surrogate use of the Ab 42/40 ratio. We used a reverse approach, classifying T1 patients into three categories according to CSF Ab 42 and the Ab 42/40 ratio, and secondarily tested the classification's relevance. Previous studies have used this reverse "CSF-to-phenotype" approach, although to our knowledge none used the Ab 42/40 ratio [21, 22, 24] . We herein showed that contrary to "true" A2T1 patients, most "false" A2T1 patients with abnormal Ab 42/40 ratios fulfill clinical criteria for amnestic or nonamnestic AD at follow-up.
The case of the "true" A2T 1 CSF profiles remains an outstanding issue. Considering that CSF tau 181P is the most specific marker of AD [12] [13] [14] 47] opens up two possibilities: (1) despite negative amyloid pathology biomarkers, "true" A2T1 cases belong to the AD spectrum or (2) despite positive tau pathology biomarkers, "true" A2T1 cases are non-Alzheimer's pathologies.
The first hypothesis raises the possibility of false-negative amyloid biomarkers. However, it seems unlikely that two consecutive-although not independent-amyloid biomarkers, namely Ab 42 and the Ab 42/40 ratio, yield false-negative results in so many cases. Moreover, the Ab 42/40 ratio was shown to have an excellent negative predictive value against amyloid PET status [48] . Alternatively, "true" A2T1 patients may have AD-type tau pathology while displaying few or no amyloid pathology. This situation has been described in young individuals without any cognitive impairment [49] as well in the primary age-related tauopathy (PART) of older individuals [47] . PART is associated with mild episodic and semantic memory impairment as well as attention and executive deficits [50] , a phenotype that corresponds only to a minority of our "true" A2T1 patients. The status of CSF tau Table 1 Comparisons between "false" and "true" A2T1 groups " biomarkers in PART is currently unknown, and whether PART belongs to the AD spectrum is also a matter of intense debate [49, 50] . The second hypothesis raises the possibility of false-positive tau 181P results. However, most "true" A2T1 patients had frankly pathological CSF tau 181P levels and a concomitant elevation of CSF T-tau, supporting a genuine positivity of tau pathology biomarkers.
Alternatively, "true" A2T1 cases may be non-AD pathologies with positive tau pathology biomarkers. Interestingly 24/50 "true" A2T1 had a clinical phenotype consistent with FTLD before the LP. Among them, nine patients fulfilled bvFTD criteria and four patients had a PSP/CBD phenotype. It would be tempting to assume that such patients correspond to FTLD with neuroglial tau pathology (FTLD-tau) [51] . Consistently in a recent clinicopathological correlation study, CSF tau 181P levels were shown to be positively associated with cerebral tau burden in FTLD, even after exclusion of cases with concomitant AD pathology [52] . However, the other phenotypes in our study (e.g., semantic dementia, n 5 10) were suggestive of TDP-43 pathology [53] , which was proven in the two cases that bore C9ORF72 mutations.
In line with the latter, surprising results came from clinical cohorts of patients with C9ORF72 mutations and available AD CSF biomarkers [54] , as well as from clinical cohorts of putative young-onset AD that had a systematic C9ORF72 mutation screening [55] . Both studies showed that Ab 42 and/or tau 181P can be abnormal in a subset of patients bearing C9ORF72 mutations. Concomitant AD pathology is a possible explanation, although the young age of onset and negative amyloid markers of our "true" A2T1 cases make it unlikely. Overall, although we do not discard that some "true" A2T1 patients may be due to false-negative amyloid biomarkers or false-positive tau biomarkers, most "true" A2T1 cases probably correspond to FTLD (and possibly PART) cases, suggesting that some FTLDs are associated with elevated tau biomarkers.
In a broader perspective, "true" A2T1 cases belong to the SNAPs, a concept forged in 2012 to designate A2T1 and/or N1 cases, that is, cases with positive tau biomarkers and/or neurodegeneration markers in neuroimaging (atrophy and/or hypometabolism) [27, 56] . SNAP is not a rare finding in healthy elderly individuals, representing up to 25% of the population, and the relevance of this finding is questionable since SNAP profile does not seem to be associated with cognitive decline [57] . In the population with cognitive decline, the SNAP group is heterogeneous, encompassing cerebrovascular disease, Lewy-body dementia, argyrophilic grain disease, and FTLD or nonspecific hippocampal sclerosis [58] . Within SNAP cases, few studies distinguished A2T1N1 from A1T-N1. A recent survey from a large AD biomarker database showed that 64% of A2N1 cases were T1 [59] . However, this study used high T-tau to define N1, leaving out N1 patients determined by neuroimaging (where atrophy and/or hypometabolism define N1). Furthermore, the Ab 42/40 ratio was not used, which overestimates the number of A2T1N1 cases. Altogether, A2T1N1 probably represents a minority of SNAP cases. We show that identification of T1 cases in SNAP is relevant from a clinical point of view because most of them may correspond to FTLD.
The two main limitations of the study are the retrospective methodology and the lack of pathological confirmation of the diagnoses. These limitations however do not outweigh the main interest of this multicenteric study, resting in its observational nature. Patients included come from daily care practices, patient groups were established and analyzed in an unbiased way, and the main analysis was based on diagnoses made before the LP. If confirmed by further studies, our results will be easy to generalize to the general population of memory clinic patients. Even if we cannot provide proof that "true" A2T1 cases are underlain by FTLD pathology, patient follow-up (and in a few cases genetics) strengthened or confirmed the diagnosis made before the CSF biomarker results.
The third limitation of this study lies in the use of what could appear as arbitrary thresholds to define biomarker positivity, raising the possibility that more stringent thresholds would have yielded very different results. This limitation is shared by all biomarker studies. However, the thresholds we used were defined by multicenter harmonization studies [34, 41] . While we do not deny that some of our cases may correspond to false-positive tau 181P results, tau 181P was clearly in the pathological range for most patients and associated with elevated T-tau. Furthermore, the rather homogeneous phenotype of "true" A2T1 patients comforts the relevance of our results.
Finally, the changes in clinical diagnoses following biomarker analysis should be considered with caution because CSF results may influence clinicians, raising a risk of circular reasoning. This is particularly true in the "false" A2T1 group, where pathological Ab 42/40 results may have influenced the clinician toward an AD diagnosis. For this reason, our study primarily focused on diagnoses made before the LP. However, changes in diagnoses following biomarker results in the "true" A2T1 group are of particular interest. First, this situation, deemed uninformative in the 2011 criteria, is equivalent to an absence of biomarkers for most clinicians. Second, although the clinician was possibly influenced toward a non-AD diagnosis, the nature of the diagnosis still holds interest.
Overall, our results suggest the Ab 42/40 ratio should be systematically calculated in case of discrepancy between normal CSF Ab 42 (A2) and high CSF tau 181P (T1) because it will reclassify half of cases as A1T1. FTLD is probably the leading cause of A2T1 profiles when defined by the Ab 42/40 ratio, and FTLD should be considered in all SNAP cases.
